#United States #New York #Lucid Diagnostics #PAVmed #Veris Health

Business Update from PAVmed Inc.

On November 13, 2026, PAVmed Inc. (NASDAQ: PAVM) provided an insightful overview of its business and preliminary financial figures for the third quarter of 2026, a noteworthy period for the diversified medical technology company. This update reflects the company's commitment to advancing in the medical device, diagnostics, and digital health sectors.

Key Highlights

PAVmed's CEO, Dr. Lishan Aklog, expressed optimism regarding PAVmed's various initiatives, particularly the implications of their subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD). Lucid has recently secured Medicare reimbursement for the EsoGuard® esophageal DNA Test, marking a pivotal milestone for the company. This change opens up significant revenue opportunities aligned with their commercial strategy, since Lucid is the largest single shareholder in PAVmed. The EsoGuard test is crucial for early detection of esophageal precancer, mitigating risks associated with esophageal cancer, a condition that impacts many lives annually.

Another subsidiary, Veris Health Inc., is demonstrating robust growth in its operational capacity. This includes advancements towards a FDA submission of their new implantable physiological monitor and a strategic collaboration with the Ohio State University in patient enrollment for clinical studies. Veris aims to enhance personalized cancer care through innovative remote monitoring technologies.

Besides the encouraging news from Lucid and Veris, PAVmed provided updates concerning their other subsidiary, Octeris Medical Inc. Progress has been made towards clinical testing of a next-generation multimodal imaging probe, with an anticipated FDA pre-submission package to be submitted shortly.

Financial Performance Overview

For the quarter ending September 30, 2026, PAVmed reported operating expenses amounting to approximately $6.8 million, which included significant stock-based compensation. Notably, the company had cash and equivalents totaling $8.9 million, a substantial increase compared to $1.5 million last December. The non-GAAP adjusted net loss stood at around $1.2 million, translating to a loss of $(0.19) per common share, reflecting PAVmed's ongoing investments into growth and operations.

PAVmed utilizes non-GAAP financial measures to provide clearer insight into its operational effectiveness and financial health. This approach enhances transparency and assists investors in assessing the company's actual performance, independent of non-cash and extraordinary items that could distort the picture.

Strategic Implications

The developments outlined in PAVmed's latest report suggest a strategic positioning that could lead to substantial shareholder value in the long term. The Medicare reimbursement for EsoGuard opens doors not only for increased revenue flow but also solidifies Lucid's competitive edge in the market for esophageal cancer detection. The progress of Veris Health and Octeris in their respective domains adds to PAVmed’s diversified and resilient portfolio, showcasing the company's commitment to innovation in healthcare technology.

This solid financial footing enhances PAVmed's ability to navigate the complex landscape of medical technology, suggesting a bright outlook as they continue to push forward with both operational and product development objectives in 2027 and beyond. PAVmed's comprehensive business strategy underscores the continual pursuit of impactful healthcare solutions, which remains a fundamental aspect of its mission and vision.

As the company continues its path toward positive transformation and growth, updates from forthcoming financial statements and operational reports will certainly be awaited by industry analysts and stakeholders alike. PAVmed's commitment to addressing pressing healthcare challenges, paired with strategic financial management, positions it strongly within the medical technology sector.

To learn more about PAVmed and its exciting developments, please visit pavmed.com.